St George’s, University of London research has found that a drug normally given to osteoporosis sufferers could provide effective pain relief to patients with knee and hip osteoarthritis.
Bisphosphonates are a group of drugs known to change the structure of bone and are most often prescribed to patients with osteoporosis, a condition characterised by fragile bones.
It is unknown, however, whether these drugs could be used to reduce pain and discomfort for patients with the joint condition osteoarthritis, which causes cartilage damage, bony growths and sore tissue.
The researchers used existing studies to assess the effectiveness of a variety of bisphosphonates in patients suffering from osteoarthritis of the hand, knee, spine and hips.
Of 3832 patients studied, in most cases these drugs showed limited pain relief. However, a few studies did show benefit; the bisphosphonate alendronate was found to be more effective for patients with hip osteoarthritis than existing pain relieving drugs. Moreover, the use of zoledronate and alendronate, specific forms of bisphosphonates, improved pain in patients with knee and hip osteoarthritis at six months —but longer term studies are needed.
Dr Nidhi Sofat, lead researcher, said: “Osteoarthritis is the most common form of arthritis worldwide. It causes damage to bone and cartilage in the joints of affected people. Most treatment is focused around pain relief, as no robust treatments have been discovered that slow down the progression of the disease.
“Our study looked at whether there were any bisphosphonate drugs that have been shown to influence pain and/or disease progression that could be used in osteoarthritis treatment.
“We found that, generally, bisphosphonates are ineffective at managing pain associated with osteoarthritis. But zoledronate and alendronate, which are specific forms of bisphosphonates, do show the potential for effective pain management specifically in patients with knee and hip osteoarthritis.
The Latest on: Bisphosphonates
- Osteoporosis Drugs Market Analysis & Global Forecast to 2022 on October 19, 2017 at 12:33 am
To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segments by drug class (bisphosphonates, calcitonins, selective estrogen receptor ... […]
- Finding the right osteoporosis medication on October 18, 2017 at 2:54 pm
Bisphosphonates are less expensive than the alternatives, are safe in the long term, and are effective in preventing fractures. Still, some women aren’t sufficiently helped by bisphosphonates, and some can’t take them due to issues with swallowing ... […]
- Generic vs Brand Bone Drug for Breast Cancer, Skeletal Mets on October 18, 2017 at 10:53 am
The answer to this question can vary depending on who you ask." The costs associated with SRE-related events, such as the costs of monitoring and treating renal events with bisphosphonates, providing additional rehabilitation care, and lost productivity ... […]
- Medication-related osteonecrosis of the jaw (MRONJ): treatment and prevention on October 17, 2017 at 10:13 pm
MRONJ is an adverse reaction seen in some patients taking medication commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab and anti-angiogenic agents) that results in progressive destruction of bone in the mandible or ... […]
- Viking Therapeutics: Conquering The Market For Aging Therapies on October 17, 2017 at 6:00 pm
He compared the dual benefit from prospective treatment with VK5211 to current standard-of-care osteoporosis pharmacotherapy, bisphosphonates (alendronate). Binkley also added that he saw potential therapeutic benefit in treating patients who underwent ... […]
- Less might be more when it comes to bisphosphonates on October 15, 2017 at 10:45 pm
New evidence has added to concerns about the benefit of very long-term bisphosphonate use. An analysis of more than 5120 postmenopausal women — the largest to assess fracture risk in older, female, long-term bisphosphonate users — supports ... […]
- Bisphosphonates for osteoporosis weakens bones: study on January 24, 2017 at 10:00 pm
It's winter and the black ice and slippery sidewalks cause lots of falls. And that's bad news if you have osteoporosis — it could cause a broken hip. Osteoporosis is thinning of the bones, and it is a huge health concern. According to the National ... […]
via Google News and Bing News